Advertisement

Topics

Merck Eprova AG Company Profile

18:27 EDT 25th September 2017 | BioPortfolio

Eprova has modern laboratories; we always keep equipment and infrastructure for chemical synthesis, production and analysis up to the current standards in technology. As a matter of course we also place high demands on safety and environmental protection. To us quality is not just another catchword. It is our commitment. Co-ordinated by our Quality-Assurance team, we serve you with top quality according to cGMP rules. Eprova is regularly inspected and has the relevant official authorisations. Our greatest challenge is to keep constantly abreast of current knowledge. For this reason, we attach great importance to our training. Our employees are all highly qualified and highly motivated to carry out your orders to your upmost satisfaction. In overlapping matters, our Microdepartments co-operate very closely. Experts from "Synthesis and Development", "Analytics", "Biology/Biochemistry", "Product Manufacturing", "Literature/Patents", "Quality Assurance" and "Safety/Environment" complement each other optimally. This close internal network is the guarantee for the comprehensive and interdisciplinary realisation of your project. We offer you a prompt and unbureaucratic but, at the same time, sound and reliable execution of your orders. Working with Eprova means for you that you no longer have to plan for a peak capacity.

Location

Im latermencker 5
Scharrhausen
CH-8200
Switzerland

Contact

Phone: 41(52)630 72 72
Fax: 41(52)630 72 55
Email: info@eprova.com


News Articles [1264 Associated News Articles listed on BioPortfolio]

Merck Foundation established

Merck, a leading science and technology company, today announced the establishment of the Merck Foundation. Through this foundation Merck combines many of its corporate responsibility activities under...

Merck Versus Merck: The Moniker Row Simmers In India

The legal battle between the ‘German’ Merck and the ‘US’ Merck over use of their shared moniker is unfolding in...   

Executive Board Changes at Merck

The Personnel Committee of E. Merck KG has decided on changes in the responsibilities of the Executive Board of Merck KGaA, Darmstadt, effective September 1, 2017. Walter Galinat (61) will hand over...

Merck erzielt Pharma-Erfolg mit neuer Tablette: Die EU hat das Medikament Cladribin von Merck zugelassen. ...

Die EU hat das Medikament Cladribin von Merck zugelassen. Es soll das erste Mittel gegen Multiple Sklerose sein, das oral verabreicht wird. Für die schwächelnde Merck-Sparte ist die Zulassung ein g....

Merck pays PDL $19.5mm to settle Keytruda patent lawsuit and gain patent rights

Merck & Co. Inc. and PDL Biopharma Inc. settled a patent infringement lawsuit brought against Merck in 2015 in which PDL claimed that Merck's solid and blood cancer drug Keytruda (pembrolizumab) infri...

Merck Ventures adds to series A investment in Macrophage Pharma

Merck Ventures, the venture capital arm of the German pharmaceutical group Merck KGaA has invested in…

Merck plant Verlagerung von Stellen in Niedriglohnländer - Zeitung

FRANKFURT (Dow Jones)--Der Darmstädter Pharma- und Spezialchemiekonzern Merck will laut einem Zeitungsbericht große Teile der Finanz-Tochtergesellschaft Merck Accounting Solutions & Services Europ.....

PRESSESPIEGEL/Unternehmen: MERCK, GRAMMER, REMONDIS, GOLDMAN SACHS, BERLIN HYP

Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires. MERCK - "Merck ohne Pharma kann ich mir nicht vorstellen", sagte Konzernchef Stefan Oschmann in einem Int...

PubMed Articles [11 Associated PubMed Articles listed on BioPortfolio]

Merck KGaA lands four Vertex cancer programs.

Merck KGaA, F-Star shake on immune-oncology bispecifics.

Zinplava Tackles Toxins Of Hard-to-Treat C. Difficile.

Merck has recently received FDA approval for bezlotoxumab (Zinplava), as a treatment to reduce recurrence of C. diffcile in patients 18 years of age or older who are receiving antibiotic treatment for...

Reactivation of Herpes Zoster Keratitis With Corneal Perforation After Zoster Vaccination.

We present a case of reactivated herpes zoster keratouveitis of 6 years duration with corneal perforation requiring penetrating keratoplasty shortly after inoculation with herpes zoster vaccine (Zosta...

CHEMGENIE: integration of chemogenomics data for applications in chemical biology.

Increasing amounts of biological data are accumulating in the pharmaceutical industry and academic institutions. However, data do not equal actionable information, and guidelines for appropriate data ...

Clinical Trials [76 Associated Clinical Trials listed on BioPortfolio]

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix®), comparing it to Merck's MMR vaccine (M-M-R®II), which is approved for...

Study of EMD531444 in Subjects With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Darmstadt, Germany, June 17 2010 - Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome ...

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

The purpose of this study is to support licensure of GSK Biologicals' MMR vaccine (Priorix®) in the US by generating immunogenicity and safety data in contrast to the US standard of care,...

Immunogenicity of GSK Bio's HPV Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

HPV infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV-16/18 L1 VLP AS04 vaccine which targets the 2 most common oncogenic HPV typ...

Companies [134 Associated Companies listed on BioPortfolio]

Merck Eprova AG

Eprova has modern laboratories; we always keep equipment and infrastructure for chemical synthesis, production and analysis up to the current standards in technology. As a matter of course we also pla...

Merck Foundation

The Merck Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a global health care leader, the Foundation is funded entirely by the company an...

The Merck Foundation

The Merck Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a global health care leader, the Foundation is funded entirely by the company an...

Merck & Co

Here you will find an overview of our activities in the core businesses of pharmaceuticals and chemicals. We illustrate the structure of our company. We present the Executive Board of Merck KGaA. ...

Merck Animal Health

Today's Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global ...

More Information about "Merck Eprova AG" on BioPortfolio

We have published hundreds of Merck Eprova AG news stories on BioPortfolio along with dozens of Merck Eprova AG Clinical Trials and PubMed Articles about Merck Eprova AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Merck Eprova AG Companies in our database. You can also find out about relevant Merck Eprova AG Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record